We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
+77.83%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$631M
AUM Growth
+$534M
Cap. Flow
+$332M
Cap. Flow %
52.62%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
FIRY
Firy Inc
FIRY
+$346M
2
COGT icon
Cogent Biosciences
COGT
+$833K

Top Sells

Rank Stock Value
1
SURF
Surface Oncology, Inc. Common Stock
SURF
+$14.8M

Sector Composition

Rank Sector Weight
1 Communication Services 74.99%
2 Healthcare 25.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FIRY
1
Firy Inc
FIRY
$163M
$466M 73.8%
+1,164,220
New +$346M
NTLA icon
2
Intellia Therapeutics
NTLA
$1.67B
$87.9M 13.93%
1,615,321
– –
SURF
3
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$27.2M 4.31%
2,945,453
-1,700,000
-37% -$14.8M
SPRO icon
4
Spero Therapeutics
SPRO
$73M
$26.7M 4.23%
1,376,968
– –
COGT icon
5
Cogent Biosciences
COGT
$7.24B
$10.3M 1.63%
916,196
+75,812
+9% +$833K
SNAP icon
6
Snap
SNAP
$9.01B
$7.52M 1.19%
150,160
– –
SYBX
7
DELISTED
Synlogic
SYBX
$5.73M 0.91%
176,798
– –

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q4 2020 Portfolio in Review

As of Q4 2020, Atlas Venture Associates IX held 7 positions worth $631M, up 553% from $96.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX deployed $332M of net new capital in Q4 2020, opening 1 new position and adding to 1 existing holding. Its largest new stake was Firy Inc: 1,164,220 shares worth $466M.

By sector, the portfolio is most concentrated in Communication Services at 75% of assets, up from 4.1% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was Surface Oncology, Inc. Common Stock, an estimated $14.8M trimmed.

  • Atlas Venture Associates IX's largest Q4 2020 buy was Firy Inc: 1,164,220 shares worth $466M.
  • Atlas Venture Associates IX added most to Cogent Biosciences in Q4 2020, an estimated $833K increase.
  • Atlas Venture Associates IX's biggest Q4 2020 reduction was Surface Oncology, Inc. Common Stock, cutting an estimated $14.8M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $631M portfolio in Q4 2020.
  • Atlas Venture Associates IX opened 1 new position and closed 0 in Q4 2020.
  • Atlas Venture Associates IX's portfolio value rose 553% quarter-over-quarter to $631M.

Based on Atlas Venture Associates IX's 13F filing for Q4 2020, filed 3 Feb 2021.